In conclusion, interim PET/CT is a valuable prognostic tool in the management of Hodgkin and non-Hodgkin lymphoma, providing early insights into treatment efficacy and prognosis. The strong correlation with end-of-treatment PET/CT, along with its high sensitivity, specificity, and negative predictive value, supports its use in clinical practice for early decision-making. By identifying patients who may require treatment intensification or escalation, interim PET/CT helps clinicians personalize treatment approaches and optimize patient outcomes. Given its high NPV, it also plays a critical role in sparing patients from unnecessary treatment intensification, thereby reducing potential treatment-related toxicity and improving quality of life.